
Neuromuscular
Latest News
Advertisement
CME Content
Advertisement




The assistant professor of neurology at the University of Washington in St. Louis discussed a study she and colleagues conducted which revealed significant differences between practitioners in diagnosing cerebral palsy.

In addition to increased motor milestone achievement, the safety profile of risdiplam was consistent with that observed in previous studies, with no new safety signals identified.



















Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 24, 2020.

Alnylam Pharmaceuticals recently completed enrollment in the phase 3 HELIOS-A clinical trial of the drug.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Newly Unveiled EPIC Trial Pins Myasthenia Gravis Medications Nipocalimab Against Efgartigimod for Efficacy
2
Revisiting the Salem Witch Trials Through a Modern Neurological Lens
3
Episode 153: Overviewing the 2025 Alzheimer's Association's Blood-Based Biomarker Guidelines
4
Efgartigimod Treatment for CIDP Leads to Increased Spending, Study Shows
5







































